INDEMNIFICATION AGREEMENTIndemnification Agreement • June 2nd, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [_______], 2020 between Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), and [_____] (“Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 2nd, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 28, 2020 (the “Effective Date”), is made and entered into by and among Larimar Therapeutics, Inc., a Delaware corporation (f/k/a Zafgen, Inc.) (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement, dated as of May 28, 2020, by and among the Company and the Investors (the “Securities Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Securities Purchase Agreement unless otherwise defined herein.
EMPLOYMENT AGREEMENTEmployment Agreement • June 2nd, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (the “Agreement”) is made on June 1, 2020 by and between LARIMAR THERAPEUTICS, INC. (the “Company”) and MICHAEL CELANO (the “Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 2nd, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 28, 2020, by and among Larimar Therapeutics, Inc., a Delaware corporation (f/k/a Zafgen, Inc.), with headquarters located at Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004 (the “Company”), and the investors listed on the Schedule of Investors attached hereto (individually, an “Investor” and collectively, the “Investors”).
FORM OF PRE-FUNDED WARRANT LARIMAR THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCKPre-Funded Warrant Agreement • June 2nd, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Larimar Therapeutics, Inc., a Delaware corporation (f/k/a Zafgen, Inc.) (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date (the “Initial Exercisability Date”), until exercised in full, [•] fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Pre-funded Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 16. This Warrant is one of the Pre-Funded Warrants to purchas
